Perfuze Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $24.4M

  • Investors
  • 10

Perfuze General Information

Description

Developer of a thrombectomy device platform designed to simplify and accelerate clot removal during acute ischemic stroke treatment. The company offers a large-lumen aspiration catheter architecture with preserved lumen integrity and streamlined device design, enabling neurointerventional clinicians to achieve effective clot removal with fewer procedural steps and reliable vessel access.

Contact Information

Website
www.perfuze.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 6, Galway Business Park
  • Dangan
  • Galway H91 W7CP
  • Ireland
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • Unit 6, Galway Business Park
  • Dangan
  • Galway H91 W7CP
  • Ireland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Perfuze Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 01-Oct-2024 $24.4M Completed Clinical Trials - General
4. Early Stage VC (Series A) 09-Feb-2022 Completed Pre-Clinical Trials
3. Grant 01-Dec-2020 Completed Pre-Clinical Trials
2. Grant 01-Jul-2019 $2.82M $3.5M Completed Pre-Clinical Trials
1. Seed Round 29-Jan-2019 $3.5M $3.5M Completed Pre-Clinical Trials
To view Perfuze’s complete valuation and funding history, request access »

Perfuze Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A Participating Preferred
Series A Participating Preferred
Series A Participating Preferred 11,352 $0.001111 $240.15 $240.15 1x $240.15 5.56%
SSPP 18,619 $0.001111 $182.94 $182.94 1x $182.94 9.12%
To view Perfuze’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Perfuze Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a thrombectomy device platform designed to simplify and accelerate clot removal during acute ischemic strok
Surgical Devices
Galway, Ireland
46 As of 2026

West Jordan, UT
 

Campbell, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Perfuze Competitors (2)

One of Perfuze’s 2 competitors is Route 92, a Venture Capital-Backed company based in West Jordan, UT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Route 92 Venture Capital-Backed West Jordan, UT
Imperative Care Venture Capital-Backed Campbell, CA
You’re viewing 2 of 2 competitors. Get the full list »

Perfuze Patents

Perfuze Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12239797-B2 Corrugated catheters Active 18-Jun-2019
US-20250319280-A1 Corrugated catheters Pending 18-Jun-2019
EP-3986519-A1 Improvements in corrugated catheters Active 18-Jun-2019
EP-3986519-B1 Improvements in corrugated catheters Active 18-Jun-2019
EP-4613215-A2 Improvements in corrugated catheters Pending 18-Jun-2019 A61M25/0053
To view Perfuze’s complete patent history, request access »

Perfuze Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Perfuze Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT PE/Buyout Minority
V-Ventures Corporation Minority
EQT Life Sciences Venture Capital Minority
Seroba Life Sciences Venture Capital Minority
SV Health Investors PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Perfuze FAQs

  • When was Perfuze founded?

    Perfuze was founded in 2018.

  • Where is Perfuze headquartered?

    Perfuze is headquartered in Galway, Ireland.

  • What is the size of Perfuze?

    Perfuze has 46 total employees.

  • What industry is Perfuze in?

    Perfuze’s primary industry is Surgical Devices.

  • Is Perfuze a private or public company?

    Perfuze is a Private company.

  • What is Perfuze’s current revenue?

    The current revenue for Perfuze is .

  • How much funding has Perfuze raised over time?

    Perfuze has raised $53.4M.

  • Who are Perfuze’s investors?

    EQT, V-Ventures, EQT Life Sciences, Seroba Life Sciences, and SV Health Investors are 5 of 10 investors who have invested in Perfuze.

  • Who are Perfuze’s competitors?

    Route 92 and Imperative Care are competitors of Perfuze.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process